Active — Not RecruitingNot Applicable

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

United States100 participantsStarted 2020-07-08

Plain-language summary

This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients * Primary brain tumors (separated by World Health Organization \[WHO\] grade I-IV) * History of seizures secondary to brain tumor * On tumor directed treatment * Magnetic resonance imaging (MRI) within 2 weeks of clinic visit where seizure assessment takes place Exclusion Criteria: * Patients without seizures * Patients with intracranial lesions other than primary brain tumor * Patients not undergoing tumor directed treatment * Absence of recent (within 2 weeks) MRI

What they're measuring

Rate of change of seizure frequency

Timeframe: Baseline to 2 years

Status of tumor

Timeframe: Up to 2 years

Trial details

NCT IDNCT04553757

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-30

View on ClinicalTrials.gov More Brain Neoplasm trials